Search

Your search keyword '"Storti, Gabriella"' showing total 21 results
Start Over Author "Storti, Gabriella"
21 results on '"Storti, Gabriella"'

1. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Author

Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano

Published
2022
Full Text
View/download PDF

2. Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin in Patients with Hematological Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical and Matched Unrelated Donors: A Real-Life Experience

Author

Serio, Bianca, primary, Storti, Gabriella, additional, D’Addona, Matteo, additional, Santoro, Lidia, additional, Frieri, Camilla, additional, De Novellis, Danilo, additional, Marano, Luana, additional, De Santis, Giovanna, additional, Guariglia, Roberto, additional, Manfra, Ilenia, additional, Urciuoli, Eleonora, additional, Luponio, Serena, additional, Marotta, Serena, additional, Morini, Denise, additional, Rizzo, Michela, additional, Palmieri, Fausto, additional, Cantore, Nicola, additional, Giudice, Valentina, additional, Risitano, Antonio Maria, additional, and Selleri, Carmine, additional

Published
2024
Full Text
View/download PDF

3. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

Author

Serio, Bianca, primary, Grimaldi, Francesco, additional, Ammirati, Lucia, additional, Annunziata, Mario, additional, De Santis, Giovanna, additional, Perrotta, Alessandra, additional, De Novellis, Danilo, additional, Giudice, Valentina, additional, Morini, Denise, additional, Storti, Gabriella, additional, Califano, Catello, additional, Risitano, Antonio Maria, additional, Pane, Fabrizio, additional, and Selleri, Carmine, additional

Published
2024
Full Text
View/download PDF

4. Intestinal and Extraintestinal Findings of Graft-versus-Host Disease on CT: A Case Series with Radiological and Histopathological Correlations.

Author

Brogna, Barbara, Frieri, Camilla, Risitiano, Antonio Maria, Urciuoli, Luigi, Storti, Gabriella, Santoro, Lidia, Urciuoli, Eleonora, De Chiara, Giovanni, Cretella, Pasquale, Sementa, Carmen, Musto, Lanfranco Aquilino, and Maccioni, Francesca

Subjects
HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease, SMALL intestine, BILIARY tract, COMPUTED tomography
Abstract

Graft-versus-host disease (GVHD) is an expected and relatively common complication after allogeneic hematopoietic stem cell transplantation. It may affect different organs and typically involves the skin, liver, and gastrointestinal tract (GI-GVHD). GI-GVHD may show heterogeneous presentations with peculiar diagnostic implications. Although an endoscopic biopsy is considered the "gold standard" for the diagnosis of GI-GVHD, its broad application is limited due to the poor clinical conditions usually present in these patients, including thrombocytopenia. In the emergency department, enhanced computed tomography (CECT) has emerged as the best imaging modality for the evaluation of GI damage in frail patients. However, the role of CT in the context of either acute or chronic GI-GVHD has not been systematically investigated. Herein, we focus on the radiological features found on CECT in five patients with GI-GVHD confirmed on histology. CECT was performed for the persistence of GI symptoms in three cases (case 1, case 3, and case 4), for small bowel occlusion in one case (case 5), and for acute GI symptoms in one case (case 2). Serpiginous intestinal wall appearance with multisegmental parietal thickness and homogeneous, mucosal, or stratified small bowel enhancement were common features. Colic involvement with segmental or diffuse parietal thickness was also present. One patient (case 5) presented with inflammatory jejunal multisegmental stenosis with sub-occlusion as a chronic presentation of GI-GVHD. Regarding mesenterial findings, all five patients presented comb signs in the absence of lymphadenopathy. Extraintestinal findings included biliary tract dilatation in two cases (case 2 and case 4). These data support the utility of appropriate radiological investigation in GI-GVHD, paving the way for further serial and systematic investigations to track the appearance and evolution of GI damage in GVHD patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Mazza, Patrizio, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Fabbiano, Francesco, Tafuri, Agostino, Chierichini, Anna, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Foà, Robin, Alati, Caterina, La Sala, Edoardo, Fazi, Paola, Vignetti, Marco, Maurillo, Luca, Buccisano, Francesco, Del Principe, Maria Ilaria, Irno-Consalvo, Maria, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Lo-Coco, Francesco, Arcese, William, and Amadori, Sergio

Published
2019
Full Text
View/download PDF

6. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Arena, Valentina, Palmieri, Raffaele, Filì, Carla, Carella, Angelo Michele, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Curti, Antonio, Luppi, Mario, Ingrosso, Claudia, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Mulè, Antonino, Tafuri, Agostino, Cudillo, Laura, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Trisolini, Silvia Maria, Alati, Caterina, La Sala, Edoardo, Maurillo, Luca, Del Principe, Maria Ilaria, Irno Consalvo, Maria Antonietta, Divona, Maria Domenica, Ottone, Tiziana, Cerretti, Raffaella, Sconocchia, Giuseppe, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, and Buccisano, Francesco

Published
2024
Full Text
View/download PDF

7. P1539: INFECTION-RELATED MORTALITY CLINICAL-BIOLOGICAL SCORING SYSTEM (IRM-SCORE) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VALIDATION STUDY IN GITMO CENTRES

Author

Clerici, Daniela, primary, Liberatore, Carmine, additional, Rancoita, Paola Maria, additional, Dellacasa, Chiara Maria, additional, Patriarca, Francesca, additional, Corradini, Paolo, additional, Saccardi, Riccardo, additional, Carella, Angelo Michele, additional, Santarone, Stella, additional, Musso, Maurizio, additional, Iori, Anna Paola, additional, Chiusolo, Patrizia, additional, Onida, Francesco, additional, Mordini, Nicola, additional, Gobbi, Marco De, additional, Galieni, Piero, additional, Luppi, Mario, additional, Aglietta, Massimo, additional, Vallisa, Daniele, additional, Storti, Gabriella, additional, Facchini, Luca, additional, Peccatori, Jacopo, additional, Ruggeri, Annalisa, additional, Greco, Raffaella, additional, Corti, Consuelo, additional, Bonifazi, Francesca, additional, and Ciceri, Fabio, additional

Published
2023
Full Text
View/download PDF

8. Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors.

Author

Oswald, Laura B., Venditti, Adriano, Cella, David, Cottone, Francesco, Candoni, Anna, Melillo, Lorella, Cairoli, Roberto, Storti, Gabriella, Salutari, Prassede, Luppi, Mario, Albano, Francesco, Martelli, Maria Paola, Cuneo, Antonio, Tafuri, Agostino, Trisolini, Silvia Maria, Tieghi, Alessia, Fazi, Paola, Vignetti, Marco, and Efficace, Fabio

Published
2023
Full Text
View/download PDF

9. Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

Author

Venditti, Adriano, primary, Piciocchi, Alfonso, additional, Palmieri, Raffaele, additional, Arena, Valentina, additional, Candoni, Anna, additional, Calafiore, Valeria, additional, Melillo, Lorella MA, additional, Cairoli, Roberto, additional, De Fabritiis, Paolo, additional, Storti, Gabriella, additional, Salutari, Prassede, additional, Lanza, Francesco, additional, Martinelli, Giovanni, additional, Luppi, Mario, additional, Capria, Saveria, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Buzzatti, Elisa, additional, Voso, Maria Teresa, additional, Ottone, Tiziana, additional, irno Consalvo, Maria, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Arcese, William, additional, Amadori, Sergio, additional, and Buccisano, Francesco, additional

Published
2021
Full Text
View/download PDF

10. Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

Author

Martino, Massimo, primary, Pitino, Annalisa, additional, Gori, Mercedes, additional, Bruno, Benedetto, additional, Crescimanno, Alessandra, additional, Federico, Vincenzo, additional, Picardi, Alessandra, additional, Tringali, Stefania, additional, Ingrosso, Claudia, additional, Carluccio, Paola, additional, Pastore, Domenico, additional, Musuraca, Gerardo, additional, Paviglianiti, Annalisa, additional, Vacca, Adriana, additional, Serio, Bianca, additional, Storti, Gabriella, additional, Mordini, Nicola, additional, Leotta, Salvatore, additional, Cimminiello, Michele, additional, Prezioso, Lucia, additional, Loteta, Barbara, additional, Ferreri, Anna, additional, Colasante, Fabrizia, additional, Merla, Emanuela, additional, Giaccone, Luisa, additional, Busca, Alessandro, additional, Musso, Maurizio, additional, Scalone, Renato, additional, Di Renzo, Nicola, additional, Marotta, Serena, additional, Mazza, Patrizio, additional, Musto, Pellegrino, additional, Attolico, Immacolata, additional, Selleri, Carmine, additional, Canale, Filippo Antonio, additional, Pugliese, Marta, additional, Tripepi, Giovanni, additional, Porto, Gaetana, additional, Martinelli, Giovanni, additional, Carella, Angelo Michele, additional, and Cerchione, Claudio, additional

Published
2021
Full Text
View/download PDF

11. Letermovir Prophylaxis For Cytomegalovirus Reactivation in Allogeneic Stem Cell Transplantation: A Multicenter Italian Real-world Experience

Author

Paviglianiti, Annalisa, Pitino, Annalisa, Carella, Angelo Michele, Bruno, Benedetto, Crescimanno, Alessandra, Federico, Vincenzo, Picardi, Alessandra, Tringali, Stefania, Ingrosso, Claudia, Carluccio, Paola, Pastore, Domenico, Vacca, Adriana, Serio, Bianca, Storti, Gabriella, Mordini, Nicola, Leotta, Salvatore, Cimminiello, Michele, Prezioso, Lucia, Loteta, Barbara, Ferreri, Anna, Colasante, Fabrizia, Merla, Emanuela, Giaccone, Luisa, Busca, Alessandro, Musso, Maurizio, Scalone, Renato, Di Renzo, Nicola, Marotta, Serena, Mazza, Patrizio, Musto, Pellegrino, Attolico, Immacolata, Selleri, Carmine, Gori, Mercedes, Tripepi, Giovanni, Porto, Gaetana, and Massimo Martino

Published
2021

12. Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors

Author

Oswald, Laura B, primary, Venditti, Adriano, additional, Cella, David, additional, Cottone, Francesco, additional, Candoni, Anna, additional, Melillo, Lorella, additional, Cairoli, Roberto, additional, Storti, Gabriella, additional, Salutari, Prassede, additional, Luppi, Mario, additional, Albano, Francesco, additional, Martelli, Maria Paola, additional, Cuneo, Antonio, additional, Tafuri, Agostino, additional, Trisolini, Silvia Maria, additional, Tieghi, Alessia, additional, Fazi, Paola, additional, Vignetti, Marco, additional, and Efficace, Fabio, additional

Published
2021
Full Text
View/download PDF

13. Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Author

Palmieri, Raffaele, primary, Buccisano, Francesco, additional, Piciocchi, Alfonso, additional, Arena, Valentina, additional, Candoni, Anna, additional, Melillo, Lorella MA, additional, Calafiore, Valeria, additional, Cairoli, Roberto, additional, De Fabritiis, Paolo, additional, Storti, Gabriella, additional, Salutari, Prassede, additional, Lanza, Francesco, additional, Martinelli, Giovanni, additional, Luppi, Mario, additional, Capria, Saveria, additional, Maurillo, Luca, additional, Del Principe, Maria Ilaria, additional, Paterno, Giovangiacinto, additional, Voso, Maria Teresa, additional, Ottone, Tiziana, additional, Lavorgna, Serena, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Arcese, William, additional, and Venditti, Adriano, additional

Published
2020
Full Text
View/download PDF

19. ELN2017 risk stratification improves outcome prediction when applied to the prospective, GIMEMA AML1310 protocol. ELN 2017 risk to guide treatment strategy in AML

Author

Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, Fabritiis, Paolo de, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno-Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano

Abstract

The 2017 version of the ELN recommendations, by integratingcytogenetics and mutational status of specific genes,sort out patients with Acute Myeloid Leukemia into 3 prognostically distinct risk categories: favorable(ELN2017-FR), intermediate(ELN2017-IR) and adverse(ELN2017-AR). We performed a post-hoc analysis of the GIMEMA AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population.

Published
2021
Full Text
View/download PDF

20. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Author

Luca Maurillo, Adriano Venditti, Maria Teresa Voso, Paolo de Fabritiis, Giovanni Martinelli, Marco Vignetti, Gabriella Storti, Mario Luppi, Francesco Buccisano, Francesco Lanza, Valentina Arena, Giovangiacinto Paterno, Lorella Melillo, Prassede Salutari, Roberto Cairoli, Serena Lavorgna, Paola Fazi, Anna Candoni, Tiziana Ottone, Alfonso Piciocchi, Maria Antonietta Irno Consalvo, Saveria Capria, Raffaele Palmieri, Maria Ilaria Del Principe, William Arcese, Valeria Calafiore, Buccisano, F, Palmieri, R, Piciocchi, A, Arena, V, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, de Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Capria, S, Maurillo, L, Del Principe, M, Paterno, G, Consalvo, M, Ottone, T, Lavorgna, S, Voso, M, Fazi, P, Vignetti, M, Arcese, W, Venditti, A, Buccisano, Francesco, Palmieri, Raffaele, Piciocchi, Alfonso, Arena, Valentina, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Capria, Saveria, Maurillo, Luca, Del Principe, Maria Ilaria, Paterno, Giovangiacinto, Irno Consalvo, Maria Antonietta, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, Arcese, William, and Venditti, Adriano

Subjects
medicine.medical_specialty, Humans, Neoplasm, Residual, Prognosis, Prospective Studies, Risk Assessment, Transplantation, Homologous, autologous stem cell transplantation, post hoc analysi, overall survival, Article, remission, male, allogeneic stem cell transplantation, MED/15 - MALATTIE DEL SANGUE, Internal medicine, medicine, Overall survival, Mutational status, human, outcome assessment, business.industry, cytogenetic, adult, flow cytometry, Complete remission, Myeloid leukemia, Hematology, prediction, Settore MED/15, major clinical study, female, Acute myeloid leukemia, gimema aml1310, outcome prediction, risk stratification, Risk stratification, survival analysi, minimal residual disease, treatment outcome, Population study, Risk categorization, business, Outcome prediction, intermediate risk patient, prospective study
Abstract

The 2017 version of the European LeukemiaNet (ELN) recommendations, by integrating cytogenetics and mutational status of specific genes, divides patients with acute myeloid leukemia into 3 prognostically distinct risk categories: favorable (ELN2017-FR), intermediate (ELN2017-IR), and adverse (ELN2017-AR). We performed a post hoc analysis of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population. In this trial, after induction and consolidation, patients in complete remission were to receive an autologous stem cell transplant (auto-SCT) if categorized as favorable risk or an allogeneic stem cell transplant (allo-SCT) if adverse risk. Intermediate-risk patients were to receive auto-SCT or allo-SCT based on the postconsolidation levels of measurable residual disease as measured by using flow cytometry. Risk categorization was originally conducted according to the 2009 National Comprehensive Cancer Network recommendations. Among 500 patients, 445 (89%) were reclassified according to the ELN2017 criteria: ELN2017-FR, 186 (41.8%) of 455; ELN2017-IR, 179 (40.2%) of 445; and ELN2017-AR, 80 (18%) of 455. In 55 patients (11%), ELN2017 was not applicable. Two-year overall survival (OS) was 68.8%, 51.3%, 45.8%, and 42.8% for the ELN2017-FR, ELN2017-IR, ELN2017-not classifiable, and ELN2017-AR groups, respectively (P < .001). When comparing the 2 different transplant strategies in each ELN2017 risk category, a significant benefit of auto-SCT over allo-SCT was observed among ELN2017-FR patients (2-year OS of 83.3% vs 66.7%; P = .0421). The 2 transplant procedures performed almost equally in the ELN2017-IR group (2-year OS of 73.9% vs 70.8%; P = .5552). This post hoc analysis of the GIMEMA AML1310 trial confirms that the ELN2017 classification is able to accurately discriminate patients with different outcomes and who may benefit from different transplant strategies. This trial was registered as EudraCT number 2010-023809-36 and at www.clinicaltrials.gov as #NCT01452646.

Published
2021

21. Synergistic antitumor effect of Doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines.

Author

Capone F, Guerriero E, Sorice A, Colonna G, Storti G, Pagliuca J, Castello G, and Costantini S

Subjects
Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Dose-Response Relationship, Drug, Drug Synergism, Hep G2 Cells, Humans, Liver Neoplasms pathology, Antibiotics, Antineoplastic administration & dosage, Carcinoma, Hepatocellular drug therapy, Doxorubicin administration & dosage, Immunosuppressive Agents administration & dosage, Liver Neoplasms drug therapy, Tacrolimus administration & dosage
Abstract

Hepatocellular carcinoma is the fifth most common cancer worldwide and shows a complex clinical course, poor response to pharmacological treatment, and a severe prognosis. Thus, the aim of this study was to investigate whether tacrolimus (FK506) has synergistic antitumor effects with doxorubicin on two human hepatocellular carcinoma cell lines, Huh7 and HepG2. Cell viability was analyzed by Sulforhodamine B assay and synergic effect was evaluated by the software CalcuSyn. Cell apoptosis was evaluated using Annexin V and Dead Cell assay. Apoptosis-related protein PARP-1 cleaved and autophagy-related protein expressions (Beclin-1 and LC3B) were measured by western blotting analysis. Cytokines concentration in cellular supernatants after treatments was studied by Bio-Plex assay. Interestingly the formulation with doxorubicin and tacrolimus induced higher cytotoxicity level on tumor cells than single treatment. Moreover, our results showed that the mechanisms involved were (i) a strong cell apoptosis induction, (ii) contemporaneous decrease of autophagy activation, understood as prosurvival process, and (iii) downregulation of proinflammatory cytokines. In conclusion, future studies could relate to the doxorubicin/tacrolimus combination effects in mice models bearing HCC in order to see if this formulation could be useful in HCC treatment.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results